International registry for Blastic Plasmacytoid Dendritic Cell Neoplasm
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
This study is creating a global database for people with Blastic Plasmacytoid Dendritic Cell Neoplasm to gather information on their experiences and treatments to help improve care for this rare cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Immune Oncology Research Institute Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 20 sites (Miami, Florida and 19 other locations) |
| Trial ID | NCT05430971 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive international registry for patients diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare hematologic malignancy. It will collect data on clinical presentations, diagnostic criteria, treatment regimens, and patient outcomes to better understand the disease. The registry will facilitate collaboration among various centers to evaluate prognostic factors and develop data-driven treatment recommendations. By gathering extensive information, the study seeks to address the lack of consensus on optimal treatment strategies for BPDCN.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm.
Not a fit: Patients without a confirmed diagnosis of BPDCN will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and outcomes for patients with BPDCN.
How similar studies have performed: While there have been studies on BPDCN, this registry approach is novel and aims to fill a significant gap in data collection for this rare condition.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of BPDCN * Signed informed consent form for prospective patients Exclusion Criteria: \-
Where this trial is running
Miami, Florida and 19 other locations
- Sylvester Comprehensive Cancer Center, University of Miami — Miami, Florida, United States (Recruiting)
- Moffitt Cancer Center — Tampa, Florida, United States (Recruiting)
- Seattle Children's Cancer and Blood Disorders Center — Seattle, Washington, United States (Recruiting)
- Hematology Center named after prof. R. Yeolyan — Yerevan, Armenia (Recruiting)
- University of Calgary — Calgary, Alberta, Canada (Recruiting)
- Children's Hospital of Eastern Ontario, University of Ottawa — Ottawa, Ontario, Canada (Recruiting)
- Cyprus Society of Haematology — Nicosia, Cyprus (Recruiting)
- Oncology Center, Mansoura University Faculty of Medicine — Al Mansurah, Egypt (Recruiting)
- M. Iashvili Children's Central Hospital — Tbilisi, Georgia (Recruiting)
- Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences — New Delhi, India (Recruiting)
- Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad — Baghdad, Iraq (Recruiting)
- University of Perugia - Azienda Ospedaliera Perugia — Perugia, Italy (Recruiting)
- Department of Biomedicine and Prevention, University of Rome Tor Vergata — Roma, Italy (Recruiting)
- Department of hematology, Kuwait Cancer Control Center — Kuwait City, Kuwait (Recruiting)
- Fundeni Clinical Institute, Department of Acute Leukemia — Bucharest, Romania (Recruiting)
- China Medical University Children's Hospital — Taichung, Taiwan (Recruiting)
- Turkish Pediatric Cancer Registry — Ankara, Turkey (Türkiye) (Recruiting)
- Istanbul University, Oncology Institute — Istanbul, Turkey (Türkiye) (Recruiting)
- University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit — Istanbul, Turkey (Türkiye) (Recruiting)
- Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group — Chelmsford, Essex, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Astghik Voskanyan, MD — Immune Oncology Research Institute, Yerevan, Armenia
- Study coordinator: Astghik Voskanyan, MD
- Email: astghikvos@gmail.com
- Phone: +374 10 28 38 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.